Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock enjoyed a major increase of 11.6% on 6/28/24. The shares closed at $5.60. Moreover, exceptionally high trading volume at 1120% of normal accompanied the advance. The stock has been extremely weak relative to the market over the last nine months but has risen 37.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 98 but a very low Power Rating of 8, and the Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment